Overview
Squamous cell carcinoma (SCC) of the cornea is a malignant neoplasm that arises from the epithelial cells of the ocular surface. It typically presents as a slow-growing, firm, elevated lesion with potential for local invasion and metastasis, particularly if left untreated. SCC of the cornea often affects older individuals, with risk factors including chronic ultraviolet (UV) light exposure, immunosuppression, and prior ocular surface diseases such as chronic conjunctivitis or pterygium. Early diagnosis and appropriate management are crucial to prevent complications such as corneal perforation, vision loss, and metastatic spread.
Diagnosis
Diagnosis of corneal SCC typically begins with a thorough clinical examination, including slit-lamp biomicroscopy to identify characteristic features such as a raised, ulcerated lesion with feathered edges and a central keratinization or crust. Biopsy confirmation is essential, often achieved through superficial or deep corneal scrapings or biopsies. Histopathological examination reveals the hallmark features of SCC, including atypical squamous cells with keratinization and intercellular bridges. Additional diagnostic tools may include imaging modalities like ultrasound biomicroscopy (UBM) or optical coherence tomography (OCT) to assess tumor depth and extent, although these are more supportive than definitive diagnostic methods.
Management
Medical Management
Postoperative pain management is a critical aspect of care following surgical interventions for corneal SCC. A randomized, double-masked trial [PMID:18500088] evaluated the efficacy of nepafenac, an NSAID, in reducing postoperative pain. The study found that nepafenac significantly decreased pain levels on postoperative days 1 and 2 compared to placebo, indicating its potential benefit in enhancing patient comfort during the early recovery period. This reduction in pain without compromising epithelial healing times suggests that nepafenac can be a valuable adjunct in the postoperative regimen. Clinicians may consider prescribing nepafenac to alleviate discomfort while ensuring that healing processes are not adversely affected, thereby improving overall patient compliance and satisfaction.
Surgical Management
The primary surgical approach for treating corneal SCC involves excisional techniques aimed at complete removal of the tumor while preserving as much healthy ocular tissue as possible. Common methods include:
The choice of surgical technique depends on the size, depth, and location of the SCC, as well as the patient's overall ocular health and visual needs. Postoperative care often includes the use of topical antibiotics and antifungals to prevent infection, along with corticosteroids to manage inflammation.
Adjuvant Therapies
In cases where there is a high risk of recurrence or metastasis, adjuvant therapies may be considered. These can include:
Monitoring and Follow-Up
Regular follow-up is essential to monitor for recurrence and manage any complications. Patients should undergo periodic slit-lamp examinations, often with additional imaging if indicated, to ensure complete resolution of the lesion and to detect any early signs of recurrence or metastasis. Long-term surveillance typically spans several years, with the frequency and intensity of follow-ups tailored to the initial severity and response to treatment.
Complications
Despite advancements in surgical techniques and adjuvant therapies, complications associated with the management of corneal SCC can arise. The study [PMID:18500088] highlighted that nepafenac did not significantly impact the time to complete corneal epithelial healing, suggesting that while pain management is improved, the risk of healing-related complications such as delayed epithelialization remains similar to placebo. However, other potential complications include:
Clinicians must remain vigilant for these complications and tailor management strategies accordingly, balancing pain control with the need for optimal healing and functional outcomes. Regular monitoring and prompt intervention for any signs of complications are crucial in ensuring the best possible prognosis for patients with corneal SCC.
References
1 Caldwell M, Reilly C. Effects of topical nepafenac on corneal epithelial healing time and postoperative pain after PRK: a bilateral, prospective, randomized, masked trial. Journal of refractive surgery (Thorofare, N.J. : 1995) 2008. link
1 papers cited of 3 indexed.